Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Arecor Therapeutics's Enterprise Value is €19.86 Mil.
Arecor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.74 Mil. Therefore, Arecor Therapeutics's EV-to-OCF for today is -7.25.
The historical rank and industry rank for Arecor Therapeutics's EV-to-OCF or its related term are showing as below:
STU:6UI'
s EV-to-OCF Range Over the Past 10 Years
Min: -62.13 Med: -6.06 Max: -1.04
Current: -7.59
During the past 9 years, the highest EV-to-OCF of Arecor Therapeutics was -1.04. The lowest was -62.13. And the median was -6.06.
STU:6UI's EV-to-OCF is ranked better than 65.04% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs STU:6UI: -7.59
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arecor Therapeutics's PE Ratio (TTM) for today is calculated as:
Arecor Therapeutics's share price for today is €0.685.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arecor Therapeutics EV-to-OCF Related Terms
Arecor Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arecor Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's EV-to-OCF falls into.
Arecor Therapeutics's current Enterprise Value is €19.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (STU:6UI) has a EV-to-OCF of -7.25 as of Aug. 01, 2026. According to the industry distribution chart, Arecor Therapeutics ranks #493 out of 1410 companies in the Biotechnology industry, placing it in the top 35%.
Is Arecor Therapeutics' EV-to-OCF too high?
Arecor Therapeutics' current EV-to-OCF is -7.25. Based on the distribution chart, Arecor Therapeutics ranks #493 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #493 out of 1410 companies for EV-to-OCF. This puts Arecor Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Arecor Therapeutics's current EV-to-OCF is -7.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current EV-to-OCF of -7.25. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current EV-to-OCF is -7.25. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current EV-to-OCF is -7.25 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
EV-to-OCF: -7.25
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for STU:6UI
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
